Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse(TM) Dermal Filler Products at 2024 SCALE Meeting

Stock Information for Evolus Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Evolus Inc.

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance
Evolus to Hold Investor Day on September 12, 2024
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia
Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference
Evolus to Report Second Quarter Financial Results on July 31, 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.